SEC Form 4 · accession 0001140361-16-072935
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jean Jacques Bienaime
Officer — Chief Executive Officer · Director
Period of report
Jul 18, 2016
Accepted (ET)
Jul 20, 2016 · 7:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 18, 2016 | M | 41,666 | $17.54 | A | 420,250 | D | |
| Common StockF1,F2 | Jul 18, 2016 | S | 41,666 | $92.72 | D | 378,584 | D | |
| Common Stock | holding | — | — | — | 25,758 | I | Shares held by Bienaime Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy Common Stock)F1,F3 | $17.54 | Jul 18, 2016 | M | 41,666 | D | May 20, 2007 | Nov 19, 2016 | Common Stock | 41,666 | 166,668 | D |
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on August 17, 2015. Mr. Bienaime's former spouse will receive approximately 17% of the net proceeds from the sale of these shares pursuant to a marital separation agreement between Mr. Bienaime and his former spouse.
- F2The price in column 4 is the weighted average price. The price actually received ranged from $89.75 to $94.32. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3Reflects the number of stock options outstanding after the transaction from this specific stock option grant.